Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2008

ImmunoVaccine Technologies Receives Funding to Further Cancer and Infectious Disease Vaccine Development

  • ImmunoVaccine Technologies (IVT) will obtain C$3 million from the Atlantic Canada Opportunities Agency (ACOA) to develop new potent immune enhancement systems. The funding was received under the Atlantic Innovation Fund. The work will be a part of a C$6 million project.

    “This funding will enable us, over the next three years, to create novel vaccines for the treatment of cancer and infectious diseases,” comments Brian Lowe, vp. IVT also says that the financing will further its research collaborations and commercialization opportunities with pharmaceutical companies worldwide.

    IVT developed a vaccine-enhancement technology called the VacciMax®. It comprises a mixture of liposomes and adjuvants. The platform is able to stimulate an earlier, more powerful, long-lasting immune response that could provide a new way to treat a wide range of diseases, according to the firm.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »